A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-trimethoprim Therapy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02045160

Enrollment

1000

Registered

2014-01-24

Start date

2014-01-31

Completion date

2017-12-31

Last updated

2014-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumocystis Jirovecii Pneumonia

Brief summary

In this study, we aim to investigate the incidence of the adverse reactions, the effectiveness and the gene polymorphism associated with the plasma level of sulfamethoxazole-trimethoprim and their metabolites (including N4-acetyl-sulfamethoxazole, sulfamethoxazole hydroxylamine and sulfamethoxazole-nitroso). And we also aim to investigate the factors associated with the sulfamethoxazole-trimethoprim induced acute psychosis.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* males and females aged 20 years or older * using oral or intravenous form of sulfamethoxazole-trimethoprim

Exclusion criteria

* patients who are under 20 years of age

Design outcomes

Primary

Measure	Time frame	Description
High performance liquid chromatography for drug plasma concentration	Participants will be followed for the duration of the treatment course, an expected average of 21 days	The plasma concentration will not be measured until the patient's treatment course completed.

Countries

Taiwan

Contacts

Primary ContactJin-Han Yang, Bachelor

r01451004@ntu.edu.tw0975-103-277

Outcome results